STOCK TITAN

[SCHEDULE 13G/A] Soleno Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Soleno Therapeutics, Inc. Schedule 13G/A reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 1,001,350 shares of Soleno common stock as of June 30, 2025. That holding represents 1.99% of the class. The filing states the shares are held by funds and separately managed accounts under Nantahala’s control and that the positions were acquired and are held in the ordinary course of business, not to influence control.

Soleno Therapeutics, Inc. Nel modulo Schedule 13G/A si segnala che Nantahala Capital Management, LLC e i suoi amministratori delegati, Wilmot B. Harkey e Daniel Mack, possono essere considerati beneficiari di 1.001.350 azioni ordinarie di Soleno al 30 giugno 2025. Tale partecipazione rappresenta l'1,99% della classe. La dichiarazione precisa che le azioni sono detenute da fondi e conti gestiti separatamente sotto il controllo di Nantahala e che le posizioni sono state acquisite e sono detenute nell'ordinaria attività di gestione, senza intento di influenzare il controllo.

Soleno Therapeutics, Inc. El informe Schedule 13G/A indica que Nantahala Capital Management, LLC y sus directivos, Wilmot B. Harkey y Daniel Mack, pueden considerarse propietarios beneficiarios de 1.001.350 acciones ordinarias de Soleno a fecha 30 de junio de 2025. Esa participación representa el 1,99% de la clase. La presentación señala que las acciones están en manos de fondos y cuentas gestionadas por separado bajo el control de Nantahala y que las posiciones se adquirieron y se mantienen en el curso normal del negocio, sin intención de influir en el control.

Soleno Therapeutics, Inc. Schedule 13G/A 보고서에 따르면 Nantahala Capital Management, LLC와 그 관리 멤버인 Wilmot B. Harkey 및 Daniel Mack는 2025년 6월 30일 기준으로 Soleno 보통주 1,001,350주에 대한 실질적 소유자로 간주될 수 있습니다. 이 보유 비율은 해당 클래스의 1.99%입니다. 신고서는 해당 주식들이 Nantahala의 통제 하에 있는 펀드 및 별도 관리 계좌에 보관되어 있으며, 해당 포지션은 사업의 통상적 범위에서 취득·보유된 것으로 통제권 행사 의도가 없음을 명시하고 있습니다.

Soleno Therapeutics, Inc. Le formulaire Schedule 13G/A indique que Nantahala Capital Management, LLC et ses dirigeants Wilmot B. Harkey et Daniel Mack peuvent être considérés comme propriétaires bénéficiaires de 1 001 350 actions ordinaires de Soleno au 30 juin 2025. Cette participation représente 1,99 % de la classe. Le dépôt précise que les actions sont détenues par des fonds et des comptes gérés séparément sous le contrôle de Nantahala et que ces positions ont été acquises et sont conservées dans le cours normal des affaires, sans viser à influencer le contrôle.

Soleno Therapeutics, Inc. Im Schedule 13G/A wird berichtet, dass Nantahala Capital Management, LLC und seine geschäftsführenden Mitglieder, Wilmot B. Harkey und Daniel Mack, als wirtschaftliche Eigentümer von 1.001.350 Aktien der Soleno-Stammaktien zum 30. Juni 2025 angesehen werden könnten. Diese Beteiligung entspricht 1,99% der Klasse. Die Einreichung gibt an, dass die Aktien von Fonds und separat verwalteten Konten unter der Kontrolle von Nantahala gehalten werden und dass die Positionen im gewöhnlichen Geschäftsverlauf erworben und gehalten werden, ohne die Absicht, die Kontrolle zu beeinflussen.

Positive
  • Full disclosure of beneficial ownership: 1,001,350 shares reported for Nantahala and its managing members
  • Transparent classification as an investment adviser (IA) and statement that holdings are held in the ordinary course
Negative
  • Holding is only 1.99% of the class, below the 5% threshold that typically signals material influence or activist potential

Insights

TL;DR Nantahala reports a small, disclosed 1.99% stake in SLNO, a non-controlling position held in the ordinary course.

The filing documents a clear, verifiable economic exposure of 1,001,350 shares representing 1.99% of Soleno's outstanding common stock. Because the stake is below 5% and the reporting persons assert the position is held in the ordinary course and not for control, the direct market impact is likely limited. The filing enhances transparency about institutional ownership but does not indicate activist intent or governance change.

TL;DR Disclosure confirms beneficial ownership but shows no control signals or group formation; governance impact appears minimal.

The Schedule 13G/A classifies Nantahala as an investment adviser and lists shared voting and dispositive power over the disclosed shares for both named managing members. The report explicitly notes no sole voting or dispositive power and that the position is not held to influence control. From a governance perspective, this is routine institutional reporting without indications of coordinated action or control ambitions.

Soleno Therapeutics, Inc. Nel modulo Schedule 13G/A si segnala che Nantahala Capital Management, LLC e i suoi amministratori delegati, Wilmot B. Harkey e Daniel Mack, possono essere considerati beneficiari di 1.001.350 azioni ordinarie di Soleno al 30 giugno 2025. Tale partecipazione rappresenta l'1,99% della classe. La dichiarazione precisa che le azioni sono detenute da fondi e conti gestiti separatamente sotto il controllo di Nantahala e che le posizioni sono state acquisite e sono detenute nell'ordinaria attività di gestione, senza intento di influenzare il controllo.

Soleno Therapeutics, Inc. El informe Schedule 13G/A indica que Nantahala Capital Management, LLC y sus directivos, Wilmot B. Harkey y Daniel Mack, pueden considerarse propietarios beneficiarios de 1.001.350 acciones ordinarias de Soleno a fecha 30 de junio de 2025. Esa participación representa el 1,99% de la clase. La presentación señala que las acciones están en manos de fondos y cuentas gestionadas por separado bajo el control de Nantahala y que las posiciones se adquirieron y se mantienen en el curso normal del negocio, sin intención de influir en el control.

Soleno Therapeutics, Inc. Schedule 13G/A 보고서에 따르면 Nantahala Capital Management, LLC와 그 관리 멤버인 Wilmot B. Harkey 및 Daniel Mack는 2025년 6월 30일 기준으로 Soleno 보통주 1,001,350주에 대한 실질적 소유자로 간주될 수 있습니다. 이 보유 비율은 해당 클래스의 1.99%입니다. 신고서는 해당 주식들이 Nantahala의 통제 하에 있는 펀드 및 별도 관리 계좌에 보관되어 있으며, 해당 포지션은 사업의 통상적 범위에서 취득·보유된 것으로 통제권 행사 의도가 없음을 명시하고 있습니다.

Soleno Therapeutics, Inc. Le formulaire Schedule 13G/A indique que Nantahala Capital Management, LLC et ses dirigeants Wilmot B. Harkey et Daniel Mack peuvent être considérés comme propriétaires bénéficiaires de 1 001 350 actions ordinaires de Soleno au 30 juin 2025. Cette participation représente 1,99 % de la classe. Le dépôt précise que les actions sont détenues par des fonds et des comptes gérés séparément sous le contrôle de Nantahala et que ces positions ont été acquises et sont conservées dans le cours normal des affaires, sans viser à influencer le contrôle.

Soleno Therapeutics, Inc. Im Schedule 13G/A wird berichtet, dass Nantahala Capital Management, LLC und seine geschäftsführenden Mitglieder, Wilmot B. Harkey und Daniel Mack, als wirtschaftliche Eigentümer von 1.001.350 Aktien der Soleno-Stammaktien zum 30. Juni 2025 angesehen werden könnten. Diese Beteiligung entspricht 1,99% der Klasse. Die Einreichung gibt an, dass die Aktien von Fonds und separat verwalteten Konten unter der Kontrolle von Nantahala gehalten werden und dass die Positionen im gewöhnlichen Geschäftsverlauf erworben und gehalten werden, ohne die Absicht, die Kontrolle zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2025

FAQ

How many Soleno (SLNO) shares does Nantahala Capital Management report owning?

The filing reports 1,001,350 shares beneficially owned by Nantahala and its managing members.

What percentage of SLNO does the reported holding represent?

The reported position represents 1.99% of the outstanding common stock as of June 30, 2025.

Are the reporting persons claiming control of Soleno (SLNO)?

No. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control.

Who filed the Schedule 13G/A for SLNO?

The filing was made by Nantahala Capital Management, LLC and co-filed by managing members Wilmot B. Harkey and Daniel Mack.

What voting and dispositive power is reported for the shares?

The filing reports 0 shares with sole voting or dispositive power and 1,001,350 shares with shared voting and shared dispositive power.
Soleno Therapeutics Inc

NASDAQ:SLNO

SLNO Rankings

SLNO Latest News

SLNO Latest SEC Filings

SLNO Stock Data

4.43B
50.15M
1.83%
110.44%
11.12%
Biotechnology
Electromedical & Electrotherapeutic Apparatus
Link
United States
REDWOOD CITY